Recce Pharmaceuticals’ RECCE 327 Phase 3 Trial Hits 155 Patients Enrolled in Indonesia

A New Hope Against Antibiotic Resistance

Recce Pharmaceuticals, an Australian clinical-stage biotech, is making significant strides with its synthetic antibiotic candidate, RECCE 327. Designed to combat the growing global crisis of antimicrobial resistance, RECCE 327 offers a unique mechanism of action that disrupts bacterial energy production, enabling rapid and broad-spectrum efficacy against multidrug-resistant pathogens.

The company is currently conducting a pivotal Phase 3 clinical trial in Indonesia, enrolling patients with diabetic foot infections (DFI), a serious and complex condition exacerbated by antibiotic resistance. Interim data from 155 patients across multiple sites in Jakarta, Denpasar, and Surabaya underpin Recce’s ambition to secure regulatory approval and commercial registration in Indonesia and the wider ASEAN region by 2026-2027.

Strategic Partnerships and Regional Focus

Recce’s collaboration with PT Etana Biotechnologies, a leading Indonesian biopharmaceutical company, is central to accelerating late-stage clinical development and facilitating market entry. This partnership aligns with Indonesia’s government priorities to improve access to innovative infectious disease treatments amid a high burden of diabetes and tuberculosis.

With over 20 million adults living with diabetes in Indonesia alone, the potential impact of RECCE 327 as a topical gel for infected wounds is substantial. The product’s rapid bactericidal action, demonstrated in earlier Phase I and II trials in Australia, combined with its broad activity against resistant bacteria, positions it as a promising first-line local treatment option where current standards of care are limited.

Regulatory and Commercial Outlook

RECCE 327 has been granted Qualified Infectious Disease Product (QIDP) designation by the US Food and Drug Administration, providing 10 years of market exclusivity and fast-track approval benefits. This regulatory recognition underscores the innovative nature of Recce’s synthetic polymer platform, which is the first new class of antibiotic in over four decades.

The company’s pipeline extends beyond topical applications to intravenous and inhaled formulations targeting hospital-acquired pneumonia and burn wound infections, including collaborations with US defense agencies. These programs highlight Recce’s ambition to address critical unmet medical needs globally, supported by a robust patent portfolio and ongoing clinical development.

Challenges and Market Potential

While the interim Phase 3 data are encouraging, Recce faces the typical uncertainties of clinical development and regulatory approval processes. The global antibiotic market is highly competitive, and the company must navigate complex commercialisation pathways across diverse healthcare systems.

Nonetheless, the urgent need for novel antibiotics amid rising resistance, combined with Recce’s innovative approach and strategic regional partnerships, offers a compelling growth story. The company aims to become a global leader in synthetic anti-infectives, potentially transforming treatment paradigms for multidrug-resistant infections.